In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TissueGene Inc.

www.tissuegene.com

Latest From TissueGene Inc.

Kolon TissueGene Faces Delisting In Korea On Invossa Uncertainties

Kolon TissueGene is facing delisting in South Korea after the recent revocation of approval of gene therapy Invossa, which could fuel legal action from shareholders. The company still hopes to resume Invossa trials in the US by submitting additional data demanded by the FDA.

South Korea Gene Therapy

Korea Suspends First Approved Gene Therapy Pending Component Discrepancy Probe

South Korea’s first approved gene therapy has been suspended from sale in the country, while recruitment in an ongoing US Phase III program has been temporarily halted, after findings that an active cell component may differ from the data submitted at the time of approval. While both manufacturer and regulator see no safety risk, results from an official Korean probe are due in mid-April.

South Korea United States

Disease Modifying Status Targeted As Kolon's Novel OA Therapy Enters US Phase III

With the removal of an FDA clinical hold, Kolon TissueGene is set to begin a US Phase III trial for Invossa, its first-in-class cell and gene therapy, for osteoarthritis of the knee. The planned study, which is larger and longer than the product's Korean Phase III program, will be under the spotlight as it will determine whether Invossa can be designated as the world's first disease-modifying drug in osteoarthritis, and is being designed accordingly.

Clinical Trials Biologics

New Active Substance First Launches Rebound In 2017

2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.

Approvals Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • TissueGene Inc.
  • Senior Management
  • Kwan H Lee, MD, PhD, CEO
    Moon Soo Song, CFO
    J. Kelly Ganjei , Dir., Bus. Dev.
  • Contact Info
  • TissueGene Inc.
    Phone: (301) 921-6000
    209 Perry Pkwy., Ste. 13
    Gaithersburg, MD 20877
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register